About selinexor
Selective nuclear export inhibitor
Used for
- Multiple myeloma, with other medicines, after prior treatments.
- Diffuse large B-cell lymphoma after at least two prior treatments.
Usual adult dose
Multiple myeloma: commonly 80 mg twice weekly with bortezomib and dexamethasone, or 80 mg weekly with dexamethasone. Lymphoma: 60 mg twice weekly; schedules may vary.
Common side effects
- Low platelet counts, anemia, and other low blood counts
- Nausea, vomiting, diarrhea, or loss of appetite
- Fatigue and weight loss
- Infections, including pneumonia
Important warnings
- Can cause severe low blood counts, infections, dehydration, and electrolyte abnormalities.
- Nausea, vomiting, confusion, or dizziness can occur; monitor and report symptoms.
- May harm an unborn baby; effective contraception is needed during treatment and afterward.
- Dose changes or interruptions may be needed; blood tests and supportive medicines are commonly required.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one week after the last dose; contraception is recommended.
Breastfeeding
Do not breastfeed during treatment or for one week after the last dose.
Interactions
- Strong CYP3A inhibitors may increase selinexor exposure.
- Strong CYP3A inducers may reduce selinexor exposure.
- Medicines that prolong QT interval may increase heart-rhythm risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.